source
- Otsuka presents new data to bolster full approval bid for Voyxact in IgA nephropathyOtsuka Pharmaceutical announced that new clinical evidence has been generated for its monoclonal antibody Voyxact, aimed at treating IgA nephropathy, a chronic autoimmune kidney disease. The data,…
- Supreme Court rules generic maker Hikma does not infringe Amarin patents, easing skinny-label lawsuitsThe U.S. Supreme Court issued a unanimous decision that Hikma Pharmaceuticals did not violate patents owned by Amarin. The high court overturned a lower court ruling that had favored the brand name…